Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond

por Podar, Klaus, Leleu, Xavier
Publicado 2021

Recent advances in the treatment of multiple myeloma: a brief review

por Bobin, Arthur, Leleu, Xavier
Publicado 2022

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma

por Chacon, Aurelia, Leleu, Xavier, Bobin, Arthur
Publicado 2023

Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?

por Leleu, Xavier, Gay, Francesca, Flament, Anne, Allcott, Kim, Delforge, Michel
Publicado 2017

In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors

por Berthon, Céline, Driss, Virginie, Liu, Jizhong, Kuranda, Klaudia, Leleu, Xavier, Jouy, Nathalie, Hetuin, Dominique, Quesnel, Bruno
Publicado 2010

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNE...

por Leleu, Xavier, Iida, Shinsuke, Ola Landgren, C., Lesokhin, Alexander, Leip, Eric, Kudla, Arthur, Finn, Gregory, Qiu, Lugui
Publicado 2023

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3

por Leleu, Xavier, Raje, Noopur, Lesokhin, Alexander, Mohty, Mohamad, Nooka, Ajay, Leip, Eric, Sullivan, Sharon T., Viqueira, Andrea, Manier, Salomon
Publicado 2023

Front line treatment of elderly multiple myeloma in the era of novel agents

por Venon, Marie-Dominique, Roccaro, Aldo M, Gay, Julie, Moreau, Anne-Sophie, Dulery, Remy, Facon, Thierry, Ghobrial, Irene M, Leleu, Xavier
Publicado 2009

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe

por Terpos, Evangelos, Zambello, Renato, Leleu, Xavier, Kuehr, Thomas, Badelita, Sorina N., Katodritou, Eirini, Brescianini, Alessandra, Liang, Tony, Wetten, Sally, Caers, Jo
Publicado 2022

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel

por Leleu, Xavier, Katodritou, Eirini, Kuehr, Thomas, Terpos, Evangelos, Caers, Jo, Zambello, Renato, Brescianini, Alessandra, Liang, Tony, Wetten, Sally, Badelita, Sorina N.
Publicado 2022

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

por Usmani, Saad Z., Quach, Hang, Mateos, Maria-Victoria, Landgren, Ola, Leleu, Xavier, Siegel, David, Weisel, Katja, Shu, Xiaomei, Li, Chuang, Dimopoulos, Meletios
Publicado 2023

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma

por Bobin, Arthur, Gardeney, Hélène, Sabirou, Florence, Gruchet, Cécile, Lévy, Anthony, Nsiala, Laly, Cailly, Laura, Tomowiak, Cécile, Torregrosa, Jose, Guidez, Stéphanie, Leleu, Xavier
Publicado 2020

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

por Richardson, Paul G., Facon, Thierry, Bensinger, William I., Leleu, Xavier, Campana, Frank, Macé, Sandrine, Chiron, Marielle, van de Velde, Helgi, Mikhael, Joseph
Publicado 2021

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment

por Dimopoulos, Meletios A., Mikhael, Joseph, Terpos, Evangelos, Leleu, Xavier, Moreau, Philippe, Bladé, Joan, Kim, Jin Seok, Stockerl-Goldstein, Keith, Richardson, Paul G.
Publicado 2022

PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

por Kumar, Shaji, Leleu, Xavier, Weisel, Katja, Popat, Rakesh, Craigie, Samantha, Patel, Leena, Ramirez, Abril Oliva, Ge, Wenzhen, MA, Qiufei, Hampp, Christian, Jagannath, Sundar
Publicado 2023

Memory loss during lenalidomide treatment: a report on two cases

por Rollin-Sillaire, Adeline, Delbeuck, Xavier, Pollet, Marianne, Mackowiak, Marie-Anne, Lenfant, Pierre, Noel, Marie-Pierre, Facon, Thierry, Leleu, Xavier, Pasquier, Florence, Le Rhun, Emilie
Publicado 2013

Upregulation of miR-135b Is Involved in the Impaired Osteogenic Differentiation of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients

por Xu, Song, Cecilia Santini, Gaia, De Veirman, Kim, Vande Broek, Isabelle, Leleu, Xavier, De Becker, Ann, Van Camp, Ben, Vanderkerken, Karin, Van Riet, Ivan
Publicado 2013

Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström Macroglobulinemia

por Gaudette, Brian T., Dwivedi, Bhakti, Chitta, Kasyapa S., Poulain, Stéphanie, Powell, Doris, Vertino, Paula, Leleu, Xavier, Lonial, Sagar, Chanan-Khan, Asher A., Kowalski, Jeanne, Boise, Lawrence H.
Publicado 2015

Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article

por Bobin, Arthur, Gruchet, Cécile, Guidez, Stéphanie, Gardeney, Hélène, Nsiala Makunza, Laly, Vonfeld, Mathilde, Lévy, Anthony, Cailly, Laura, Sabirou, Florence, Systchenko, Thomas, Moya, Niels, Leleu, Xavier
Publicado 2021

Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients

por Gardeney, Hélène, Bobin, Arthur, Gruchet, Cécile, Sabirou, Florence, Lévy, Anthony, Nsiala, Laly, Cailly, Laura, Tomowiak, Cécile, Torregrosa, Jose, Moya, Niels, Hulin, Cyrille, Leleu, Xavier, Guidez, Stéphanie
Publicado 2020